How long you can take colchicine depends almost entirely on why you are taking it. For an acute gout flare, a course might last just one or two days. For gout flare prevention while starting a new medication, the standard duration is up to six months. For conditions like familial Mediterranean fever, people take colchicine every day for life. The drug’s safety profile at low doses supports prolonged use in many situations, but the answer is never one-size-fits-all, and the difference between a safe long-term dose and a dangerous one can hinge on your kidneys, your liver, or what other medications you take.
Short Courses for Acute Flares
When colchicine is used to treat a gout attack that has already started, the course is brief. Current guidelines call for a loading dose followed by a smaller dose an hour later, with the entire treatment concentrated into the first day or two. This “low-dose” acute regimen replaced older, more aggressive dosing schedules that had patients taking colchicine every hour or two until they either felt better or developed severe diarrhea. The modern approach works about as well with far fewer gastrointestinal side effects, so there is no reason to stretch an acute gout course beyond a couple of days.
Acute calcium pyrophosphate crystal arthritis (sometimes called pseudogout) and acute pericarditis also involve relatively short initial treatment windows, though pericarditis courses run considerably longer than gout flares. In a landmark trial, patients with a first episode of acute pericarditis took colchicine for three months alongside a standard anti-inflammatory drug like aspirin or ibuprofen. Patients weighing more than 70 kg received 0.5 mg twice daily, while lighter patients received 0.5 mg once daily.1PubMed. A randomized trial of colchicine for acute pericarditis So even in a condition where the course feels “short” relative to lifelong therapy, you may still be taking it daily for months.
Months-Long Prophylaxis During Gout Treatment Changes
One of the most common reasons for an extended colchicine prescription is gout flare prophylaxis when you start a urate-lowering drug like allopurinol or febuxostat. Paradoxically, lowering uric acid levels can trigger a burst of flares in the first several months of treatment. To prevent that, doctors typically prescribe low-dose colchicine alongside the new medication. A controlled trial that followed patients through this transition supported continuing colchicine prophylaxis for six months, with subjects staying on the drug for three months beyond reaching target uric acid levels.2PubMed. Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis The usual dose during this period is 0.5 or 0.6 mg once daily.
Six months is a common upper bound cited in guidelines, but some clinicians extend prophylaxis if a patient is still experiencing flares at that point. The decision depends on how quickly uric acid drops into target range and whether the patient has tophi or other signs of heavy crystal burden. If you are approaching the end of a six-month course and still getting flares, your doctor may extend it rather than leave you unprotected during a vulnerable period.
Years and Even Decades for Chronic Inflammatory Conditions
For several conditions, colchicine is not a temporary fix but a lifelong daily medication. Familial Mediterranean fever is the clearest example. In a study following 350 children on continuous colchicine at doses of 1 to 2 mg per day, treatment lasted between 6 and 13 years.3PubMed. Long-term colchicine treatment in children with familial Mediterranean fever Many of those children continue taking it into adulthood and beyond, because stopping colchicine allows inflammatory attacks to return and, more critically, exposes the kidneys to amyloidosis, a serious long-term complication of uncontrolled FMF. Behçet’s syndrome similarly calls for indefinite daily dosing, typically 0.5 to 0.6 mg twice a day.
Prophylaxis for recurrent calcium pyrophosphate crystal arthritis is another indication where people stay on colchicine long-term, sometimes indefinitely, because there is no urate-lowering equivalent to address the underlying crystal problem. In all these scenarios, the answer to “how many days” is effectively open-ended: you keep taking it as long as the condition requires it and your body tolerates it.
The Growing Use in Heart Disease
A newer and rapidly expanding indication for colchicine is cardiovascular risk reduction. Low-dose colchicine (0.5 mg daily) has been shown in large trials to reduce the risk of heart attacks, strokes, and other major cardiovascular events in people with established atherosclerotic disease. This is a chronic preventive therapy, meaning patients take it indefinitely in the same way they take a statin or aspirin.
The safety data for this use are reassuring. A comprehensive review of long-term safety concluded that aside from mild diarrhea when first starting the drug, which typically resolves within a week, continuous low-dose colchicine does not harm kidney function, liver function, or cognition. It does not increase the risk of cancer, serious infections, bleeding, or problems with fertility or wound healing.4PubMed. Low-dose colchicine for atherosclerosis: long-term safety That reassurance applies specifically to patients without significant kidney or liver impairment, a caveat that comes up repeatedly with this drug. Reports of serious side effects like bone marrow suppression or muscle toxicity were no more common than with placebo in the cardiovascular trial populations studied.
How Colchicine Works and Why Duration Matters
Colchicine tamps down inflammation by interfering with structures inside cells called microtubules. By disrupting microtubule assembly, it blocks a cascade of inflammatory signals, including the activity of white blood cells that rush to crystal deposits in joints or inflamed tissue around the heart.5PubMed Central. Colchicine — update on mechanisms of action and therapeutic uses It also suppresses a specific inflammatory complex that has become a hot topic in cardiovascular and metabolic research. This broad anti-inflammatory reach is why the same drug works for gout, pericarditis, FMF, and atherosclerosis.
The practical consequence of this mechanism is that colchicine does not cure any of these conditions. It controls inflammation for as long as you take it. Stop the drug, and the underlying inflammatory trigger (uric acid crystals, pyrophosphate crystals, a genetic autoinflammatory mutation, or vascular plaque inflammation) is still there. That is why duration is condition-specific: for a one-off gout flare, a day or two is enough to break the inflammatory cycle. For a chronic condition driven by an ongoing trigger, you need ongoing suppression.
When Kidneys or Liver Change the Equation
Colchicine is processed primarily through the liver and excreted partly through bile and partly through the kidneys. In people with healthy organs, low doses stay well below toxic thresholds.6The American Journal of Medicine. Contemporary Perspectives on the Efficacy and Safety of Colchicine: The Cincinnati Consensus Conference on Colchicine But when kidney or liver function is impaired, the drug clears more slowly and can accumulate to dangerous levels, even at standard doses.
Pharmacokinetic modeling shows just how sensitive this relationship is. With mild kidney impairment, the standard twice-daily gout prophylaxis dose can push blood levels about 23% above the safe upper limit. With moderate impairment, even once-daily dosing at the standard amount overshoots by roughly 10%. In severe kidney disease, the dose needs to drop to 0.3 mg once daily to stay in the therapeutic window.7PubMed Central. Prophylaxis of Gout Flares in Patients with Renal Impairment: Dosing Adjustments with Colchicine Oral Solution Informed by a Pharmacokinetic Model Despite these challenges, colchicine is not off-limits for people with kidney problems. A study of patients with severe chronic kidney disease who took colchicine for crystal-induced arthritis flares found it was well tolerated in about three quarters of cases when doses were kept at 0.5 mg per day or less, with a median treatment duration of six days.8PubMed Central. Safety and efficacy of colchicine in crystal-induced arthritis flare in 54 patients with severe chronic kidney disease
For liver disease, the concern is similar. Since colchicine is heavily metabolized in the liver, advanced hepatic impairment substantially extends the drug’s half-life. People with severe liver disease need adjusted dosing intervals even at low doses. The bottom line: impaired kidneys or liver do not necessarily mean you cannot take colchicine, but they do mean you may need a lower dose, a shorter course, or more frequent monitoring.
Drug Interactions That Can Turn a Safe Dose Dangerous
Even with perfectly healthy kidneys and liver, certain medications can cause colchicine to accumulate to toxic levels. The drug is broken down by a liver enzyme called CYP3A4 and pumped out of cells by a transporter called P-glycoprotein. Medications that block either of these pathways effectively raise your colchicine exposure, sometimes dramatically.
The antibiotic clarithromycin is one of the most frequently cited culprits. Case reports describe patients on stable, well-tolerated colchicine regimens who developed life-threatening toxicity after starting clarithromycin, with symptoms severe enough to mimic septic shock.9PubMed Central. CYP3A4/P-glycoprotein inhibitors related colchicine toxicity mimicking septic shock Other medications in this category include certain antifungal drugs, some HIV protease inhibitors, and grapefruit juice in large amounts. A case of neuromyopathy was reported in a patient taking colchicine alongside atorvastatin and clarithromycin, highlighting how stacking multiple interacting drugs amplifies the risk.10PubMed Central. Acute Colchicine-induced Neuromyopathy in a Patient Treated with Atorvastatin and Clarithromycin
This matters for the duration question because a colchicine course that is perfectly safe on its own can become hazardous if you start a new interacting medication partway through. If you are on long-term colchicine and get prescribed an antibiotic or antifungal, that is a conversation worth having with your pharmacist or prescriber before filling the new prescription.
What Chronic Toxicity Looks Like
Acute colchicine poisoning from an overdose is a medical emergency that unfolds in stages: gastrointestinal distress within the first day, followed by multi-organ dysfunction over the next several days, and recovery (if it happens) over the following weeks.11PubMed. Colchicine poisoning: the dark side of an ancient drug But chronic toxicity from long-term use at standard doses is a different animal. It develops gradually and can be subtle enough to miss.
The signature chronic side effect is neuromyopathy, a combination of nerve and muscle damage that causes weakness, numbness, and sometimes difficulty walking. A case report described a 61-year-old man who had taken colchicine for 23 years for gout and presented with numbness and weakness in his lower limbs. He was ultimately diagnosed with colchicine poisoning manifesting as neuromyopathy, gastric ulcers, and bone marrow suppression.12PubMed Central. Chronic colchicine poisoning with neuromyopathy, gastric ulcers and myelosuppression in a gout patient: A case report Cases like this are rare, particularly in patients with normal kidney and liver function, but they underscore the importance of periodic monitoring during long-term use. Catching early signs of muscle weakness or unexplained blood count changes allows the dose to be reduced or the drug stopped before serious damage develops.
Older Adults Need Extra Caution
Age alone does not necessarily require a dose change, but the realities of aging often do. Older adults are more likely to have some degree of kidney function decline, to be taking multiple medications that could interact with colchicine, and to have less physiological reserve if toxicity occurs. A safety evaluation found that while age by itself did not change colchicine’s pharmacokinetics enough to mandate a blanket dose reduction, the confounding effects of comorbid conditions and concomitant medications in elderly patients should be carefully evaluated.13PubMed. Are dosing adjustments required for colchicine in the elderly compared with younger patients? New Zealand’s medicines safety authority puts it more bluntly: elderly patients, even those with normal kidney and liver function, may be more susceptible to colchicine toxicity and should be closely monitored.14Prescriber Update. Spotlight on Colchicine
In practical terms, this means that an older adult starting gout prophylaxis or cardiovascular colchicine might begin at the low end of the dose range, have kidney function checked at baseline, and get periodic follow-up labs to confirm the drug is not accumulating. It does not mean colchicine is off the table for people over 65; gout and cardiovascular disease are overwhelmingly conditions of older adulthood, so excluding this population would defeat the purpose.
Pregnancy, Fertility, and Breastfeeding
Because colchicine works by disrupting cell division machinery, it has long raised theoretical concerns about birth defects and fertility. The real-world evidence, mostly from women with FMF who take the drug throughout pregnancy, is more reassuring than the theoretical risk might suggest. A systematic review and meta-analysis found that the rate of miscarriage or fetal loss was not significantly different in colchicine-exposed pregnancies compared to unexposed ones. The percentage of birth defects in exposed pregnancies ranged from about 0.6% to 4.0%, comparable to rates in women with FMF who were not taking colchicine. Fertility assessments, including sperm quality in men, showed no apparent differences between exposed and unexposed groups.15PubMed. Safety of colchicine on fertility, pregnancy, and lactation: a systematic review and meta-analysis informing the EULAR/PReS recommendations for familial Mediterranean fever
For women with FMF, stopping colchicine during pregnancy is generally discouraged because uncontrolled disease and the resulting amyloidosis pose a greater threat to both mother and baby than continuing the drug. The breastfeeding data are thinner, with only one study available, but it showed no growth differences between babies of mothers who took colchicine and those who did not. Women taking colchicine for other indications should discuss the risk-benefit balance with their doctor, but the FMF data provide a substantial body of reassurance.
Colchicine in Children
Most pediatric colchicine use is for FMF, and the safety record in children is strong. In a study of 153 children with FMF followed for several years, about 14% developed diarrhea, though only a small handful needed a dose reduction to manage it. About 12% had mild, transitory increases in liver enzyme levels during the first year, but these were not clinically significant. Blood counts and kidney function remained normal across the board, and there was no correlation between adverse effects and the child’s age, how long they had been on treatment, or any particular clinical feature of their disease.16PubMed. Colchicine is a safe drug in children with familial Mediterranean fever For families managing FMF in a child, the evidence consistently supports that the benefits of preventing attacks and amyloidosis outweigh the modest side effect profile.
Off-Label Uses in Skin Conditions
Beyond the well-established indications, colchicine sees a fair amount of off-label use in dermatology. Conditions ranging from chronic urticaria and Sweet’s syndrome to pyoderma gangrenosum, leukocytoclastic vasculitis, and recurrent aphthous stomatitis (canker sores) have been treated with colchicine at doses ranging from 0.5 mg to 2 mg daily. The duration for dermatologic uses varies widely, from short courses to ongoing suppressive therapy, depending on the condition and the patient’s response. Evidence for most of these uses is limited to case series and small studies rather than large randomized trials, so the decision to try colchicine for a skin condition typically comes after first-line treatments have failed.
If you are prescribed colchicine for a dermatologic condition, the same safety rules apply: monitor kidney and liver function, watch for drug interactions, and pay attention to gastrointestinal symptoms or muscle weakness. The off-label setting does not change the drug’s pharmacology.
How to Recognize When Something Is Going Wrong
Whether you are on a three-day course or a three-decade one, knowing the warning signs of colchicine trouble can protect you. Diarrhea is the most common side effect and often the first signal that you are near the upper edge of tolerance. If diarrhea is persistent or severe, reducing the dose usually resolves it. Nausea and abdominal cramps are in the same category.
More concerning symptoms include unexplained muscle weakness or pain, tingling or numbness in the hands or feet, easy bruising, recurrent infections, or sore throat and fever, any of which could signal bone marrow suppression or neuromyopathy. These are rare at standard doses in people with normal organ function, but they become more likely with drug interactions, kidney decline, or very prolonged use at higher doses. If you notice any of these while on colchicine, getting a blood count and muscle enzyme check can catch problems early, while they are still fully reversible.